X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES Fact Sheet, AMAR REMEDIES Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES Fact Sheet   (AMAD)

Here is the latest financial fact sheet of AMAR REMEDIES. For more details, see the AMAR REMEDIES quarterly results and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

AMAR REMEDIES Price History

Price Rs 6.1
Mkt Cap Rs m 159
Vol '000 139.7
P/E X -0.5
P/CF X 0.3
EPS (TTM) Rs -12.0
% ch % 0.5
No. of shares m 26.16
% ch week % -7.6
% ch 1-mth % -18.5
% ch 12-mth % -82.7
52 week H/L Rs 48.0/5.5
(As on Dec 11, 2013 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

AMAR REMEDIES Financials

No. of Mths
Year Ending
12
Jun-08
12
Jun-09
*
12
Jun-10
*
12
Jun-11
*
12
Jun-12
*
5-Yr Chart
Click to enlarge
AMAR REMEDIES EQUITY SHARE DATA
High Rs583979171164 
Low Rs2113247586 
Sales per share (Unadj.) Rs114.0141.1187.6228.2261.6 
Earnings per share (Unadj.) Rs8.310.212.614.917.4 
Diluted earnings per shareRs8.310.212.614.917.4 
Cash flow per share (Unadj.) Rs9.212.916.619.222.3 
Dividends per share (Unadj.) Rs01.001.001.000 
Adj. dividends per shareRs0.001.001.001.000.00 
Dividend yield (eoy) %03.81.90.80 
Book value per share (Unadj.) Rs47.656.868.383.2100.7 
Adj. book value per shareRs47.656.868.383.2100.7 
Shares outstanding (eoy) m26.1626.1626.1626.1626.16 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.30.20.30.50.5 
Avg P/E ratio x4.72.64.18.27.2 
P/CF ratio (eoy) x4.32.03.16.45.6 
Price / Book Value ratio x0.80.50.81.51.2 
Dividend payout %09.88.06.70 
Avg Mkt Cap Rs m1,0336801,3473,2183,270 
No. of employees `000NANANANANA 
Total wages/salary Rs m8380108128163 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
AMAR REMEDIES INCOME DATA
Net Sales Rs m2,9823,6924,9085,9706,844 
Other income Rs m319111021 
Total revenues Rs m2,9853,7114,9195,9806,865 
Gross profit Rs m3564756868331,131 
Depreciation Rs m2272104110128 
Interest Rs m76124208274398 
Profit before tax Rs m261298385459626 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0000-50 
Tax Rs m43325668121 
Profit after tax Rs m218266329391455 
Gross profit margin %11.912.914.014.016.5 
Effective tax rate %16.510.714.514.819.3 
Net profit margin %7.37.26.76.56.6 
AMAR REMEDIES BALANCE SHEET DATA
Current assets Rs m1,2551,7622,4713,3344,904 
Current liabilities Rs m2834766012,4703,581 
Net working cap to sales %32.634.838.114.519.3 
Current ratio x4.43.74.11.31.4 
Inventory Days Days60798593124 
Debtors Days Days83818387100 
Net fixed assets Rs m8401,0821,1621,3821,689 
Share capital Rs m262262262262262 
"Free" reserves Rs m1,0081,2441,5421,9032,358 
Net worth Rs m1,2451,4851,7882,1772,635 
Long term debt Rs m423730275507 
Total assets Rs m2,0952,8463,6334,9286,862 
Interest coverage x4.43.42.92.72.6 
Debt to equity ratio x0000.10.2 
Sales to assets ratio x1.41.31.41.21.0 
Return on assets %14.013.714.813.512.4 
Return on equity %17.517.918.418.017.3 
Return on capital %26.227.732.629.931.0 
Exports to sales %1.33.51.71.34.0 
Imports to sales %00000 
Exports (fob) Rs m381298180273 
Imports (cif) Rs m00000 
Fx inflow Rs m381298180273 
Fx outflow Rs m715412 
Net fx Rs m311147779271 
AMAR REMEDIES CASH FLOW
From Operations Rs m 20 25 -110 -18 -313 
From Investments Rs m -48 -314 -186 -471 -489 
From Financial Activity Rs m 29 295 328 571 769 
Net Cashflow Rs m 0 6 31 82 -33 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 25.5%
Foreign collaborators 0.0%
Indian inst/Mut Fund 9.2%
FIIs 0.0%
ADR/GDR 0.0%
Free float 65.3%
Shareholders 13,061
Pledged promoter(s) holding 99.7%
 

Company Information

REGD OFF B-G01, Marathon Innova, Ganpatrao Kadam Marg, Lower Parel, Mumbai-13
E-MAIL investors@amarremedies.com WEB www.amarremedies.com
TELEPHONE (022) 6556 8091 FAX NA
SECTOR CONSUMER PRODUCTS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
AUDITOR Shyam C. Agrawal & Co.
CHM: Pravin N. Shah COMP SEC: Jagdish Nagpal YEAR OF INC: 1984 BSE CODE: 532664 FV (Rs): 10 DIV YIELD (%): -

More Consumer Products Company Fact Sheets:   SHASUN PHARMA  PFIZER  INDOCO REMEDIES  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare AMAR REMEDIES With:   SHASUN PHARMA  PFIZER  INDOCO REMEDIES  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare AMAR REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex & Nifty Open at Record Highs; Banking & PSU Stocks Rally(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.46% while the Hang Seng is up 0.28%. The Shanghai Composite is trading up by 0.43%.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES - P&G HYGIENE COMPARISON

COMPARE AMAR REMEDIES WITH

MARKET STATS